59.98
+(+%)
Currency In USD
Address
4275 Executive Square
La Jolla, CA 92037
United States of America
Phone
619 592 9775
Sector
Healthcare
Industry
Biotechnology
Employees
50
First IPO Date
March 12, 2021
| Name | Title | Pay | Year Born |
| Mr. Kevin R. Lind | President, Chief Executive Officer, Secretary & Director | 1.07M | 1976 |
| Ms. Brandi L. Roberts CPA, M.B.A. | Executive Vice President & Chief Financial Officer | 662,653 | 1974 |
| Dr. Randall E. Kaye M.D. | Executive Vice President & Chief Medical Officer | 717,954 | 1962 |
| Mr. Steven W. Spector J.D. | Executive Vice President, Head of Business Development & General Counsel | 0 | 1965 |
| Mr. Chadwick J. Orevillo MPH | Executive Vice President & Head of Operations | 0 | N/A |
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.